Health-related Quality of Life in Localized and Metastatic Renal Cell Carcinoma: Insights from Patient-reported Outcome Measures.

Background and objective: Patient-reported outcome measures (PROMs) are increasingly being used to evaluate health-related quality of life (HRQoL) in cancer care. We investigated the effects of treatment for both localized (M0) and metastatic renal cell carcinoma (mRCC) on generic and cancer-specific HRQoL up to 15 wk after diagnosis. Methods: Patients were selected from the National PROspective infrastructure for renal cell carcinoma (PRO-RCC), including M0 and mRCC patients who participated in the HRQoL assessment. HRQoL was measured using the Dutch validated European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 at baseline (T Key findings and limitations: A total of 295 patients were included, of whom 217 (73.6%) had M0 disease and 78 (26.4%) had mRCC. At follow-up, 89 patients with M0 disease (41%) and 38 with mRCC (48.7%) completed the T Conclusions and clinical implications: Patients with M0 disease and mRCC experienced improvements in several functional and symptom domains within 15 wk after diagnosis. Future studies should assess the impact of these changes on treatment continuation and/or responses. Patient summary: We looked at health-related quality of life (HRQoL) in patients with localized or metastatic kidney cancer. In general, both groups reported improvements in emotional, social, and physical wellbeing at 15 weeks after their diagnosis, and results suggest further changes at 6 months after diagnosis. Patients reported improvements in symptoms such as fatigue, pain, sleep, and appetite. Our results indicate that patients can find meaningful improvements in their quality of life shortly after diagnosis and initiation of treatment.